Can lurasidone be used as an augmenting agent for obsessive‑compulsive disorder (OCD)?

Lurasidone for OCD

Lurasidone is NOT recommended as an augmenting agent for OCD, as it lacks evidence-based support and is not FDA-approved for this indication.

Evidence-Based Augmentation Strategies for Treatment-Resistant OCD

The 2019 Nature Reviews Disease Primers guideline clearly establishes the evidence-based pharmacological augmentation hierarchy for SSRI-resistant OCD 1:

First-Tier Augmentation Options:

• Risperidone and aripiprazole have the strongest meta-analytic evidence for efficacy 1
• Clomipramine augmentation showed superiority over quetiapine in the only head-to-head RCT, though carries significant safety concerns including seizures, arrhythmia, and serotonin syndrome due to drug-drug interactions 1

Second-Tier Options:

• Glutamatergic agents: N-acetylcysteine (3 of 5 RCTs positive) and memantine have demonstrated efficacy 1

Important Clinical Context:

Only one-third of patients with SSRI-resistant OCD show clinically meaningful response to antipsychotic augmentation, with effect sizes smaller than SSRI monotherapy 1. This necessitates ongoing risk-benefit monitoring, particularly for metabolic adverse effects like weight gain and metabolic dysregulation.

Why Lurasidone Is Not Recommended

FDA labeling explicitly states lurasidone is approved only for bipolar I depression (as monotherapy or adjunctive therapy with lithium/valproate), not for OCD 2.

The available research evidence is extremely limited:

• One 2025 case report in schizophrenia with comorbid OCD 3
• One 2025 observational study in anorexia nervosa with comorbid OCD showing only time-related changes without drug-specific efficacy (BF10 < 3 for group effects) 4

Neither study provides controlled evidence for lurasidone's efficacy in primary OCD treatment.

Clinical Algorithm for SSRI-Resistant OCD

When a patient fails adequate SSRI trial (8-12 weeks at maximum tolerated dose) 1:

1. First, augment with CBT if available (larger effect sizes than risperidone augmentation) 1

2. If CBT unavailable or not tolerated, pharmacological options in order:

   • Risperidone or aripiprazole (strongest evidence, best efficacy-tolerability balance) 1
   • Consider clomipramine augmentation if antipsychotics fail, with careful monitoring of drug levels and cardiac/neurological safety 1
   • N-acetylcysteine or memantine as glutamatergic alternatives 1

3. Avoid quetiapine as routine augmentation (marginal superiority over placebo) 1

4. Monitor closely for metabolic complications (weight, glucose, lipids) with any antipsychotic augmentation 1

Common Pitfalls

• Using antipsychotics not supported by evidence (including lurasidone, which has no controlled OCD data)
• Failing to optimize SSRI dose before augmentation (higher doses show greater efficacy in OCD than depression) 1
• Inadequate trial duration (minimum 8-12 weeks needed) 1
• Neglecting CBT augmentation when pharmacological options are prioritized 1

The evidence unequivocally supports risperidone or aripiprazole as first-line antipsychotic augmentation for treatment-resistant OCD, not lurasidone.